# Pat's Desk — Deep-Dive Pitches on 4 Active Names
*Prepared 2026-05-25 · Companion to `anchorage_pat_deals_and_pitch.md` Part B*

**Source.** Desk-flagged list from a contact: Aramsco, Balcan Innovations, CoAdvantage, Internet Brands, ION Trading, Soliant, Spring Windows.

**Of the 7, four are interview-deployable. Three are not, and you should know why.**

| Rank | Name | Why it's the right pitch | Anchorage signal |
|---|---|---|---|
| 1 | **Springs Window Fashions** | Dec 2024 out-of-court LME with two-AHC split is a textbook Pat-desk transaction; richly documented | NOT confirmed publicly |
| 2 | **Internet Brands** | THE 2026 LME case study — KKR coercive AHC suppression + secondary block + AI disruption narrative | NOT confirmed publicly |
| 3 | **ION Trading / ION Platform** | $10B Oct 2025 refi + stalled HoldCo PIK + Italian golden-powers + multi-silo Lux/UK | NOT confirmed (HPS/Goldman are named privates) |
| 4 | **Aramsco** | American Securities-owned $505M TLB, CCC+ Oct 2025, Jon-Don collapse sector contagion | rumored, plausible-but-unconfirmed |

**Drop:**
- **Balcan Innovations** — BDT & MSD bilateral private credit, no syndicated paper, $200M growth capex, no distress
- **CoAdvantage** — Aquiline + PrimePay merger June 2025 = integration story, not credit story; no public debt
- **Soliant Health** — Vistria B2 5.7x clean to 2031; education-anchor stable; watchlist not active

**On Anchorage involvement.** None of these have publicly-confirmed Anchorage holdings (Rule 2019 / law firm press / 13F). Pitch all of them as **questions, not claims** — exactly the framing in the master prep. The point is to demonstrate that you read the live distressed market in Pat's lane, not that you've reverse-engineered his book.

---

## 1. SPRINGS WINDOW FASHIONS — *the cleanest pitch*

### One-line thesis
> Springs is the cleanest two-AHC out-of-court LME of 2024 — FOLO/second-out structure with Wachtell on one side and Davis Polk on the other — and at 11x pre-deal leverage on a housing-dependent business, it's still not fixed. The 2028 maturity wall makes 2026-2027 the workout window.

### Why this name
- Mid-cap ($2-2.6B funded debt pre-LME) — Pat's sweet spot
- **Two-group AHC** with different counsel = documentary complexity, cooperation-agreement leverage
- Out-of-court FOLO/second-out structure = priming via consent, not via court
- 2028 maturity wall on FOLO + ABL = recoverable trade idea
- Sector exposure (US housing) makes the recovery thesis testable

### Pre-Dec 2024 capital structure
| Tranche | Size | Coupon | Maturity | Pre-deal mark |
|---|---|---|---|---|
| First-lien TLB | ~$2.0B | SOFR + ~425 | 2028 | **85-86** |
| 6.5% Sr Unsecured Notes | $625M | 6.5% | 2029 | **58.5** (deep distress) |

EBITDA run-rate ~$44M/quarter (~$176M annual) → **>11x leverage on senior secured alone**. Moody's **Caa1** with "unsustainable capital structure" call.

### The December 19, 2024 transaction
- New-money **First-Out Term Loan (FOLO) + ABL** providing fresh liquidity
- **Second-Out Term Loan** refinanced substantially all of the existing $2B 1L TLB
- **New 2L Notes** issued in exchange for a portion of the $625M unsecured notes
- ABL extended from 2026 to 2028 — removed cross-default trigger
- Sponsor: **Clearlake** (acquired 2021 from AEA + BCI)

### The advisor lineup (the tell)
| Side | Counsel | Financial Advisor |
|---|---|---|
| Company / Sponsor | Kirkland & Ellis | Centerview |
| **AHC #1** | Wachtell | Houlihan Lokey |
| **AHC #2** | Davis Polk | Perella Weinberg |
| Admin agent / RCF | Latham & Watkins | — |

**The two-AHC structure is the whole story.** Probably (a) FOLO/new-money lenders vs. (b) consenting TLB holders that rolled into Second-Out. The unsecured noteholders who didn't exchange = the primed class.

### Anchorage angle
- No Rule 2019 (out-of-court, no PACER). No press release names Anchorage.
- The **structurally most likely Anchorage position** would be the FOLO/first-out — they prefer top-of-waterfall + new-money optionality (same posture as their 2026 First Brands DIP secondary buy).
- Use the J.Crew DIP-to-exit conversion analogy: the FOLO providers get priming + a TLB roll into Second-Out + extension of ABL = same playbook minus the courthouse.

### Catalyst window
- **2026-2027:** Housing recovery (or not) drives EBITDA trajectory
- **2028:** FOLO + ABL refi
- **Watch for:** S&P/Moody's upgrade/downgrade actions; any disclosure of next year's revenue/EBITDA via private placement filings; Clearlake's exit timing (5-yr hold approaching)

### Interview deployment
> *"The Springs Window Fashions December exchange is the one I keep going back to as a clean two-AHC out-of-court template — Wachtell-Houlihan on one side, Davis Polk-Perella on the other, with a FOLO/Second-Out priming structure. The question I'd love to understand is how the cooperation between the two groups got written: was it a single co-op covering both, or did each AHC have its own and they negotiated to each other? Because at 11x going in, with the unsecured paper at 58 and a Caa1 rating, the priming math on the second-out is doing all the work, and the 2L exchange ratio for the unsecureds is the only piece I'd want to stress-test against a downside housing scenario."*

This question (a) shows you read the docs, (b) names the FAs and counsel correctly, (c) doesn't require you to claim Anchorage was in either group, (d) opens a thread Pat can run with.

### Risks if you overclaim
- Don't say Anchorage was in either AHC — not publicly confirmed
- Don't claim leverage post-deal — wasn't disclosed
- Don't conflate FOLO/Second-Out with a J.Crew DIP — same logic, different mechanic

### Sources
- [Davis Polk — Springs Window Fashions capital raise](https://www.davispolk.com/experience/springs-window-fashions-capital-raise-and-refinancing-transaction)
- [Latham — Springs new capital infusion](https://www.lw.com/en/news/2024/12/latham-watkins-advises-on-springs-window-fashions-completed-new-capital-infusion-to-support-growth)
- [Debtwire — Springs creditors form group](https://ionanalytics.com/insights/debtwire/springs-window-fashions-lenders-form-group/)
- [Bloomberg (Jul 2024) — creditors organize](https://www.bloomberg.com/news/articles/2024-07-10/springs-window-creditors-organize-as-housing-crunch-hurts-demand)

---

## 2. INTERNET BRANDS — *the live 2026 story*

### One-line thesis
> The KKR-owned $4-5B Internet Brands TLB is the 2026 case study in **sponsor coercion of AHC formation** — KKR has warned lenders that organizing with restructuring advisors will cost them future primary deal allocations, and has blocked secondary loan transfers to hedge funds. Meanwhile the first-lien TLB is at ~80 on an AI-disruption narrative even as EBITDA grew 5% in Q4 2025.

### Why this name
- LIVE story — Octus headline coverage in April 2026
- Sponsor-coercion playbook is exactly what cooperation agreements were designed to defeat
- AI disruption thesis priced into the loan (high 60s at worst) while financials improving = a "narrative vs. fundamentals" credit
- 2028 maturity wall on $4.67B of second-lien paper

### Current capital structure (as of Sept 30, 2025)
| Tranche | Size | Spread | Maturity | Latest mark |
|---|---|---|---|---|
| First-Lien TLB4 | ~$2.0B | SOFR + 425 | **2031** | **bid ~79.45 / ask ~81.20** |
| Second-Lien TL | ~$4.67B aggregate | SOFR + 425 | **2028** | bid ~89.99 / ask ~91.00 |
| ABL / RCF | Not disclosed | — | — | — |

**Inversion alert:** 1L at 80 vs 2L at 90 is structurally weird. Reflects the market pricing AI risk much more severely on the 2031 paper than the 2028 — i.e., near-term 2L holders see a refi path; longer-dated 1L holders see WebMD/Medscape getting structurally disintermediated by Perplexity/ChatGPT/Google AI Overviews.

### Sponsor + co-investor stack
- **KKR** — acquired 2014, lead sponsor
- **Temasek + Warburg Pincus** — joined 2022 recapitalization
- Q4 2025: Revenue $695M (+8% YoY), adj. EBITDA $273M (+5% YoY)

### The KKR coercion playbook (this is the headline)
1. **April 2026 (9fin / Reuters):** KKR denied secondary loan transfer requests from hedge funds attempting to build positions. The credit agreement gives the borrower a CUSIP transfer consent right — KKR is using it as a structural AHC suppression tool.
2. **Octus 2026 reporting:** KKR warned current TLB holders that retaining independent restructuring counsel (i.e., joining an AHC) would jeopardize their access to **future KKR primary deal allocations** across the rest of the platform.
3. **No AHC has publicly organized.** The lender update call hosted by RBC (arranger) is the sponsor's preferred channel — a 1-to-many narrative-management call rather than 1-to-1 cooperation-agreement negotiation.

### The distress mechanic
The 1L is priced as if the WebMD/Medscape ad business is structurally impaired by AI search disintermediation. The Q4 5% EBITDA growth says the disintermediation hasn't yet hit cash flows — but if it does, the 2028 second-lien refi becomes a forced LME. KKR's incentive is to **delay AHC organization until they can either (a) IPO Henry Schein One and use proceeds to delever, or (b) sell WebMD to a strategic** — both options the AHC would price-discriminate against if organized.

### Anchorage angle
- No public confirmation. The whole point of KKR's suppression playbook is that no AHC organizes publicly.
- But: hedge fund short interest is building per Debtwire (loan shorts via TRS / synthetics).
- If Anchorage *were* in this, the cooperation-agreement work would be exactly Pat-style — but the asymmetric size ($4-5B funded debt) is **above** ACO IX's stated $200M-$1.5B sweet spot.

### Catalyst window
- **2026-2027:** WebMD ad-rev trajectory vs. AI search erosion
- **H2 2026:** Possible Henry Schein One IPO (was filed pre-acquisition; relaunch on the table)
- **2028:** Second-lien maturity wall — refi attempt or LME

### Interview deployment
> *"The Internet Brands credit is fascinating to me as a case study in sponsor coercion — KKR is blocking secondary transfers and reportedly tying primary-allocation access to lenders not organizing with restructuring counsel. The cooperation-agreement question writes itself: this is exactly the structural problem co-ops were designed to solve, except the borrower is using the primary-market access lever, not just the indenture. I'd love your view — does that lever actually work in 2026 with this many sophisticated holders, or is it just delaying an AHC that organizes the moment the loan dips below 70?"*

This (a) names the live KKR/9fin/Octus story specifically, (b) frames it as a structural question about co-op effectiveness, (c) doesn't require you to claim Anchorage is in it.

### Risks if you overclaim
- Don't claim Anchorage is in — they'd publicly be the AHC if they were, and there is no AHC
- Don't speculate on the AI-disruption thesis being right or wrong — Pat will hold an opinion you can't predict
- Don't confuse Internet Brands (KKR/health/legal verticals) with First Brands Group (auto parts, in Ch11). Easy slip in conversation.

### Sources
- [Octus — KKR warns Internet Brands lenders](https://octus.com/resources/articles/kkr-warns-internet-brands-lenders-they-could-lose-access-to-future-primary-deals-if-they-organize-with-advisors/)
- [9fin (Apr 1 2026) — KKR denies trades in IB loans](https://www.9fin.com/insights/kkr-internet-brands-loans)
- [Debtwire — investors short IB loans on AI disruption bet](https://ionanalytics.com/insights/debtwire/investors-leverage-ai-disruption-bet-with-term-loan-shorts/)
- [S&P — IB $4.8B TLB launch](https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/internet-brands-launches-4-8b-1st-lien-term-loan-commitments-due-nov-18-67647733)

---

## 3. ION TRADING / ION PLATFORM — *the European cross-border play*

### One-line thesis
> ION Platform's October 2025 $10B refi consolidated three subsidiary silos at the OpCo level — but the HoldCo carries ~$3B of HPS/Goldman PIK and ION's effort to raise a €600M preferred-equity PIK to refi division-level PIK has **stalled with multiple funds passing**. The Italian "golden powers" trap on Cedacri prevents dividends from clearing back to HoldCo. This is a slow-motion structural-subordination workout, with no Ch11 jurisdiction.

### Why this name
- Famously the most-levered private company in Europe — ~10x consolidated HoldCo leverage
- Andrea Pignataro's empire, 70%+ EBITDA margins, ~$2.3B revenue, ~$1.7B adj EBITDA
- **Multi-silo Lux S.à r.l. issuer structure** — exactly the kind of documentary complexity Anchorage prices well
- **Italian "golden powers"** regulatory veto on Cedacri dividends = unique cross-border doctrine
- October 2025 exchange offer required only **58% consent** — the holdout 42% piece is a co-op test

### Capital structure (pro forma October 2025 refi)
| Tranche | Size | Maturity | Notes |
|---|---|---|---|
| **OpCo — ION Platform Investment Group:** | | | |
| New USD TLB | $2.25B | n.a. | SOFR-based, spread not disclosed |
| New EUR TLB | €2.05B | n.a. | EURIBOR-based |
| USD SSN | $1.5B | 2032 | New issue at refi |
| EUR SSN | €500M | 2030 | New issue |
| EUR SSN | €600M | 2032 | New issue |
| **HoldCo — ION Investment Corp S.à r.l.:** | | | |
| HPS + Goldman PIK | ~$3B | various | PIK; HPS is primary |
| Various division-level PIKs | n.a. | n.a. | Targeted for €600M new-money refi — STALLED |

- **Pro forma OpCo leverage:** 5.7x (down from 6.2x pre-merger)
- **Holdco-inclusive consolidated leverage:** 10x (per S&P, end-2023)
- **Ratings:** S&P B+ / Moody's B2 stable (assigned Q4 2025)

### Sponsor / control
- **Andrea Pignataro** — founder, CEO, 100% control. No traditional PE sponsor.
- 2024 acquisitions: Cerved (€1.35B), Prelios (€1.35B) — increased Italian perimeter exposure

### The distress mechanic
**Three things are happening simultaneously:**

1. **HoldCo PIK refi stalled.** ION sought €600M preferred-equity PIK to refi division-level PIK; HPS declined to take more (concentration); other funds passed. Per Octus, "pens down" across multiple shops. Without this raise, the division-level PIK rolls at a higher rate or matures into a cash-pay wall.

2. **Italian "golden powers" block.** June 2024 — Italian court upheld government veto on €275M Cedacri bond. **Dividends from Cedacri can't flow up.** This structurally traps cash inside the Italian perimeter, accelerating the HoldCo coverage problem.

3. **Failed Feb 2024 TLB repricing.** ION pulled a $1.7B TLB repricing because **the market refused tighter spreads on consolidated 10x leverage.** Investors are price-disciplined on this credit — the October 2025 refi at par-for-par with $1.50-$2.50 per $1,000 consent fees was the workable structure, but tighter pricing remains a market-not-willing problem.

### Anchorage angle
- **No public confirmation.** This is Lux/UK-domiciled, not Ch11 — no Rule 2019.
- **Named privates: HPS Investment Partners + Goldman Sachs Private Credit** as the HoldCo PIK lenders. Not Anchorage.
- **Where Anchorage might be:** the secondary market for ION Platform 2029/2032 notes. These were exchanged in Oct 2025 at par-for-par with consent fees; market trading data behind Bloomberg paywall. The 58%-consent exchange leaves 42% who could have held out — that's where co-op work would happen.

### Catalyst window
- **Q3 2026:** Anniversary of Cerved/Prelios deals — integration disclosure
- **2026-2027:** HoldCo PIK refi — does ION find a taker for the €600M, or does the structure crack
- **2028-2029 maturity:** Some legacy notes due
- **Cross-border:** any Italian regulatory action on Cedacri / Prelios is a structural shock

### Interview deployment
> *"ION is the European credit I'd most want your view on. Three things are tied together that I can't see from the outside: the stalled €600M preferred-equity PIK at HoldCo, the Cedacri dividend trap from the Italian golden-powers ruling, and the October exchange that needed only 58% consent. The piece I find genuinely puzzling is the holdout 42% — in a US Ch11 you'd see a co-op organize around them. In a Lux S.à r.l. structure with no court forum, what's the mechanism that prevents that 42% from blocking the next refi? Is it just the absence of a scheme-of-arrangement-equivalent, or is there a contractual mechanic that ties their hands?"*

This question (a) names the three live tensions with specificity, (b) lands on a doctrinal cross-border question Pat will engage with, (c) doesn't require Max to claim Anchorage holds ION paper.

### Risks if you overclaim
- Don't pretend you've read the new ION Platform indenture — you haven't
- Don't claim ION will file Ch11 — wrong jurisdiction; would be Lux/UK scheme/RP
- Don't conflate ION Trading (subsidiary, now merged into ION Platform) with ION Group (the empire) — Pignataro brand confusion is a tell

### Sources
- [Octus — ION struggling to raise preferred-equity PIK](https://octus.com/resources/articles/ion-struggling-to-raise-preferred-equity-pik-after-lender-pushback/)
- [Bloomberg (Jan 2024) — ION's $13B private debt empire](https://www.bloomberg.com/news/articles/2024-01-24/ion-tycoon-built-fintech-empire-with-billions-of-dollars-in-private-debt)
- [Bloomberg (Feb 2024) — ION Markets pulls $1.7B repricing](https://www.bloomberg.com/news/articles/2024-02-02/ion-markets-pulls-1-7-billion-leveraged-loan-sale-for-repricing)
- [Milbank — $10B+ ION Platform refi](https://www.milbank.com/en/news/milbank-advises-ion-group-in-connection-with-ion-platforms-over-dollar10-billion-equivalent-refinancing.html)
- [Bloomberg Law — ION Group 10x leverage in 2023, S&P](https://news.bloomberglaw.com/bankruptcy-law/ion-group-holding-had-10-times-leverage-in-2023-s-p-says)

---

## 4. ARAMSCO — *the smaller fit, but the highest Anchorage probability*

### One-line thesis
> American Securities-owned restoration/abatement distributor with a $505M SOFR+475 TLB out to 2030. **CCC+ downgrade October 2025** (from B- at the Oct 2023 LBO close — two-notch slide in 24 months). Jon-Don's overnight collapse in May 2025 = sector contagion signal; Aramsco bought their assets, which absorbs a peer's customer base but strains working capital. Smallest of the four, but the only one that sits squarely in ACO IX's $200M-$1.5B sweet spot.

### Why this name
- Sub-$1B funded debt = **directly in Pat's lane**
- Recent rating action (CCC+ Oct 2025) = active distress event
- **Sector contagion** (Jon-Don) creates a discussable thesis
- 2030 TLB maturity gives runway, but a CCC+ at high-7x leverage = refi execution risk now
- American Securities is a credible sponsor (not a Cornell-style dividend recap story) = workout cooperation more likely

### Capital structure
| Tranche | Size | Spread | Maturity |
|---|---|---|---|
| First-lien TLB | ~$505M | SOFR + ~475 | October 2030 |
| ABL revolver | $80M | — | — |

- **Ratings:** S&P B- at Oct 2023 LBO close → **CCC+** at Oct 2025 downgrade
- **Implied leverage:** high-7x on sub-$100M EBITDA (no public revenue/EBITDA disclosure)

### Sponsor history
| Year | Sponsor | Event |
|---|---|---|
| ~2014 | Audax Group | Prior owner |
| pre-2023 | AEA SBF | AEA's lower-mid-market platform |
| 2023 | Odyssey Investment Partners | Brief hold |
| **Oct 2023** | **American Securities** | LBO close, Davis Polk advised on $80M ABL |

### The distress mechanic
- **Sector:** Restoration/abatement demand correlates with P&C insurance claim volume + housing/commercial construction
- **2024-2025 sector hits:** Elevated P&C premiums crimped insurer-funded remediation jobs; commercial construction softness
- **May 2025 Jon-Don collapse:** Incline Equity-backed peer ceased operations overnight due to LBO debt service. Aramsco bought the assets. This is **both a tailwind (customer pickup) and a stress signal** — same end-markets, same sponsor archetype, same leverage profile.
- **Oct 2025 S&P CCC+:** Two-notch downgrade in 24 months. CCC+ implies S&P sees default risk in the next 12-24 months absent positive change.

### Anchorage angle
- **The only name on this list that fits ACO IX's $200M-$1.5B mandate.**
- TLB at SOFR+475 trading sub-90 (inferred from CCC+; not publicly quoted)
- **Per the trifecta query and the research, this is the highest-probability Anchorage rumor name** — the size, the rating trajectory, the sponsor (American Securities is co-op-cooperative), and the sector all fit.
- No Rule 2019, no AHC press, no confirmed signal. **Treat as plausible-but-unconfirmed.**

### Catalyst window
- **2026:** Any further S&P/Moody's action (CCC+ to CCC = covenant negotiation watch)
- **2027:** Possible TLB amendment/extension if EBITDA continues to slide
- **Sector watch:** Next Incline-Equity-collapse-style peer event would force AHC organization
- **No hard maturity wall until 2030** — but at CCC+, refi execution risk is now

### Interview deployment
> *"Aramsco is the smallest name on the list but I think the most interesting from a sector-contagion angle. The S&P move to CCC+ in October — two notches in 24 months from the American Securities LBO — combined with the Jon-Don collapse in May at a similar leverage profile, makes me think the next 12 months are about whether American Securities can run an amendment-extension or whether secured holders organize before the EBITDA gets to a covenant trigger. American Securities is generally seen as a workout-rational sponsor — do you find sponsor cooperativeness actually matters in CCC+ situations, or does it always come down to the secured group having priming optionality regardless?"*

This (a) shows you read the S&P releases, (b) names the sector contagion specifically, (c) ends on a Pat-doctrine question (does sponsor type matter at CCC+) that he'll have a view on.

### Risks if you overclaim
- Don't claim Anchorage is in — plausible but unconfirmed
- Don't quote a TLB trading level — none is public
- Don't claim EBITDA — none is public; high-7x leverage is inference from the CCC+ rating math

### Sources
- [S&P — Aramsco downgraded to CCC+](https://www.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/3454077)
- [S&P — Aramsco B- assigned at LBO](https://www.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/3060132)
- [Davis Polk — $80M Aramsco financing](https://www.davispolk.com/experience/american-securities-80-million-aramsco-acquisition-financing)
- [Industrial Distribution — Jon-Don ceases operation](https://www.inddist.com/operations/news/22941782/distributor-jondon-ceases-operation-due-to-financial-hardship)
- [Cleanfax — Aramsco buys Jon-Don assets](https://cleanfax.com/aramsco-acquires-jon-dons-business-assets/)

---

## NAMES TO DROP (and why)

### Balcan Innovations — drop
- **Actual sponsor:** BDT Capital Partners (Nov 2019), now BDT & MSD Partners post-2023 merger with Michael Dell's family office
- **NOT** Yellow Wood (different consumer PE firm). **NOT** Belcan engineering services (separate company, Cognizant acquired Belcan for $1.3B in 2024).
- **Why drop:** Debt held in BDT & MSD's private credit funds (likely MSD Investment Corp BDC bilateral) — not syndicated, not traded. $200M capex expansion announced 2025-2027 = growth posture. No distress catalyst.
- **If Pat raises it:** "I looked at this — BDT's private credit shop holds the paper bilaterally and the company is in a $200M growth-capex cycle. I don't see a syndicated entry point. Did your contact mean Belcan? That was Cognizant's $1.3B acquisition last year and there's no distressed credit there either."

### CoAdvantage — drop
- Aquiline Capital + Morgan Stanley Capital Partners (now Aquiline solo post-2023)
- **Merged with PrimePay June 30, 2025** — integration story
- No public debt facility disclosures, no rating agency action
- **Why drop:** Performing credit, no syndicated paper, growth story not distress
- **If Pat raises it:** "Aquiline rolled CoAdvantage and PrimePay together last June into an integrated PEO + payroll platform. Private credit, no rated debt. I don't see a distressed angle unless your contact knows something specific about the integration."

### Soliant Health — keep on watchlist, not pitch
- Vistria Group acquired July 2024 from Olympus Partners for **$2.5B at 9.6x** EBITDA (~$261M EBITDA, ~$1.49B funded debt, **5.7x leverage, Moody's B2**)
- 80% of EBITDA is **school-based therapy (IDEA-mandated SLP/OT/PT)** — structurally resilient
- 20% is **healthcare staffing — Moody's flagged 35-40% revenue decline in 2024** as pandemic premiums normalize
- **No near-term maturity (2031 TLB)**, no LME, no Ch11
- **Why not a pitch:** Watch story, not active workout. Education anchor too stable for distress.
- **If Pat raises it:** "Vistria bought it at 9.6x from Olympus last July at $2.5B EV / 5.7x leverage. The school-based therapy business is the anchor — IDEA mandate makes SLP/OT/PT placement non-cyclical. The healthcare staffing tail is where Moody's flagged the 35-40% rev decline post-pandemic. Watchlist, not in a workout — would expect this to need a B3 downgrade before it's interesting."

---

## HOW TO USE THIS DOC

**Don't memorize all four for the room.** Pick the **one** you'd volunteer if Pat asks "what live name in our lane have you been thinking about" — and have the other three ready as "follow-up question" material if he names them himself.

**Recommended primary pitch:** **Springs Window Fashions.** It's the cleanest because:
- Closed deal — you can speak to the structure without speculating about Anchorage's position
- Two-AHC mechanic is a Pat-doctrine question
- Right size for ACO IX
- No coercion overlay (unlike Internet Brands) that forces you into uncomfortable territory

**Recommended secondary if Pat asks "anything else?":** **Internet Brands** for the live KKR coercion story (with the explicit caveat that the size is above ACO IX's stated lane).

**Use ION as the cross-border probe** if the conversation drifts to European RX, since Pat ran Altice France steerco.

**Use Aramsco only if Pat probes specifically into sub-$1B credits.**

---

## TRIFECTA CONSENSUS (4-MODEL PANEL)

Run 1 had a prompt bug (the 7 names lived in the script's docstring but not in the USER variable sent to models). **Claude refused to fabricate and correctly flagged "only one of seven names was actually transmitted."** Gemini and DeepSeek hallucinated entirely different names (Serta/Envision/Avaya / Joann/Saks/Neiman). OpenAI failed on schema (additionalProperties:false missing). Fixed and re-ran — full 4/4 success on Run 2.

### Interview-actionability scores (1-10)
| Name | OpenAI | Gemini | DeepSeek | Claude | Pattern |
|---|---|---|---|---|---|
| **Spring Windows** | **9** | **10** | **9** | **9** | **Unanimous #1** ✓ |
| **Internet Brands** | **7** | **9** | 3 | **9** | 3/4 top-3 ✓ |
| Aramsco | 2 | 1 | 6 | 6 | Split — DS/Claude weight CCC+ catalyst, OAI/Gem weight unconfirmed Anchorage |
| ION Trading | 3 | 1 | 6 | 6 | Split — same pattern; Claude/DS value the cross-border complexity |
| Soliant Health | 2 | 1 | 6 | **8** | Claude promoted to top-3 |
| Balcan Innovations | 3 | 6 | 2 | 3 | Only Gemini likes; agrees with my "drop" |
| CoAdvantage | 5 | 2 | 4 | 2 | Nobody loves; agrees with my "drop" |

### Consensus calls
- **Spring Windows** as primary pitch: unanimous lock
- **Internet Brands** as secondary: confirmed (DeepSeek's 3 is the dissent; reasoning was likely the size being above ACO IX's lane, which my doc already flags)
- **Drop CoAdvantage + Balcan:** confirmed by 3/4
- **Aramsco / ION:** legitimate split — keep as Tier 3 supplementary pitches
- **Soliant:** Claude promoted to top-3 citing the Vistria LBO underwriting + school-district budget exposure angle. My doc has Soliant as "watch, not pitch" — Claude's framing suggests a fuller writeup if the conversation goes long on healthcare staffing comps. Worth holding in the back pocket.

### Per project memory
> "Claude tends to give the most rigorous reviews in the panel."

Confirmed twice this session — Claude caught the prompt bug in Run 1, and Claude's top-3 in Run 2 included a name the simpler models dismissed because they over-weighted the absence of a confirmed Anchorage public position rather than the underlying credit setup. Take Claude's reviews seriously when the panel splits.

**Raw outputs:** `/root/tmp/trifecta_anchorage_pat_names_2026-05-25_result.json`